Routine

Chronic atrial fibrillation — anticoagulation & rate/rhythm control

Ambulatory AF management · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Long-term management of established AF centres on stroke prevention with oral anticoagulation guided by CHA2DS2-VASc, plus a choice between rate and rhythm control. Early rhythm control (within ~1 year of diagnosis) improves outcomes in symptomatic patients.

Red flags

  • New focal neurology suggesting cardioembolic stroke
  • Haemodynamic instability with fast ventricular rates
  • Syncope suggesting conduction disease or pauses
  • Pre-excited AF (broad irregular tachycardia) — avoid AV nodal blockers
  • Heart failure symptoms suggesting tachycardia-mediated cardiomyopathy

Assessment

Differential diagnosis

  • Atrial flutter
  • Multifocal atrial tachycardia
  • Frequent atrial ectopy
  • Focal atrial tachycardia
  • Sinus tachycardia with ectopy
  • Hyperthyroidism-driven AF

Investigations

  • 12-lead ECG (confirm AF, assess rate/QRS)
  • TTE (LA size, LV function, valve disease)
  • TSH, FBC, U&E, LFTs, calcium/magnesium
  • HbA1c and lipid profile for risk factors
  • Ambulatory monitor if paroxysmal/rate assessment needed
  • Renal function to guide DOAC dosing

Management

  • Confirm diagnosis on a 12-lead ECG and characterise as paroxysmal, persistent or permanent
  • Calculate CHA2DS2-VASc; offer anticoagulation if score ≥2 (men) or ≥3 (women), consider if 1 (men)/2 (women)
  • Assess bleeding risk (HAS-BLED) to flag modifiable factors, not to withhold anticoagulation
  • Start a DOAC first-line unless mechanical valve or moderate-severe mitral stenosis (then warfarin)
  • Dose-reduce DOAC for renal function, age, weight and interacting drugs per label
  • For rate control target resting HR <110 bpm (lenient) initially; aim lower if symptomatic
  • Choose rate-control agent: beta-blocker or non-dihydropyridine CCB; add digoxin if needed
  • Consider early rhythm control (antiarrhythmic or ablation) in symptomatic or recently diagnosed AF
  • Refer for catheter ablation if drug-refractory symptomatic paroxysmal AF or AF with HFrEF
  • Treat reversible drivers: hypertension, OSA, alcohol, obesity, thyroid disease
  • Never stop anticoagulation around cardioversion or ablation without a defined bridging plan
  • Arrange structured follow-up and annual reassessment of stroke/bleeding risk

Drugs & doses

Apixaban 5 mg PO BD (2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥133 µmol/L)
Rivaroxaban 20 mg PO OD with food (15 mg OD if CrCl 15-49)
Edoxaban 60 mg PO OD (30 mg if CrCl 15-50, weight ≤60 kg, or potent P-gp inhibitor)
Dabigatran 150 mg PO BD (110 mg BD if age ≥80 or bleeding risk)
Bisoprolol 2.5-10 mg PO OD for rate control
Diltiazem 180-360 mg PO daily (modified-release) if beta-blocker unsuitable and EF preserved
Digoxin 125-250 mcg PO OD (adjunct; target level 0.5-0.9 ng/mL)

Disposition

Outpatient cardiology or GP-led management; refer to electrophysiology for ablation and to specialist AF clinic if complex. Admit only for haemodynamic instability or stroke.

Complications & pitfalls

  • Ischaemic stroke / systemic embolism
  • Tachycardia-mediated cardiomyopathy
  • Major bleeding on anticoagulation
  • Bradycardia from rate-control agents
  • Proarrhythmia from antiarrhythmics

Exam pearls

  • DOACs are preferred over warfarin for non-valvular AF for equal efficacy and less intracranial bleeding
  • Aspirin alone is not adequate stroke prophylaxis in AF
  • Left atrial appendage occlusion is an option when long-term anticoagulation is contraindicated
  • Rhythm control earlier in the disease course yields the greatest benefit
  • Weight loss and risk-factor control reduce AF burden and ablation recurrence

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.